Tirzepatide
Dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound)
A dual GIP and GLP-1 receptor agonist and an approved prescription medicine. Head-to-head trials showed greater weight reduction than semaglutide at comparable timepoints.
- Category
- Fat Loss & Metabolic
- Half-life
- Approximately 5 days
- Cycle length
- Continuous, under medical supervision
- Level
- advanced
Overview
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The dual mechanism was originally pursued for glycaemic control, and the weight results turned out to exceed what single-receptor agonists had achieved. Like semaglutide, it is a regulated medicine included here because it is central to modern metabolic discussion, not because research powder is a reasonable substitute.
How it works
GIP and GLP-1 are both incretin hormones released after eating. Activating both receptors appears to produce greater appetite suppression and improved insulin sensitivity than GLP-1 agonism alone. Tirzepatide is modified for albumin binding, giving it a weekly dosing interval.
Reported benefits
- Greater average weight reduction than semaglutide in head-to-head comparison
- Strong glycaemic control
- Improved appetite regulation
- Ongoing outcome trials reporting cardiovascular benefits
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Prescription escalation begins at 2.5 mg weekly for four weeks, then 5 mg, with further steps to 7.5, 10, 12.5 and 15 mg weekly. Escalation is driven by tolerability.
As with semaglutide, the clinical titration schedule assumes a manufactured, precisely dosed product. Reconstituted research powder cannot replicate that, and the commonest serious errors are concentration miscalculations.
Prescribed titration: 2.5 mg weekly for four weeks, then 5 mg, with onward steps to 10, 12.5 and 15 mg. Community reports follow it closely, and the higher steps are the ones most often described as triggering nausea.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
SURMOUNT-1 reported average weight reductions of over 20% at the highest dose over 72 weeks. SURPASS-2 showed tirzepatide outperformed semaglutide 1 mg on both HbA1c and weight. Cardiovascular outcome data has since followed. The evidence is strong and the mechanism is well understood — which again makes the case for using it as a supervised medicine rather than as a powder.
Preclinical & non-clinical data
A dual GIP and GLP-1 receptor agonist; animal work shows greater weight loss than GLP-1 agonism alone, and the incretin mechanism is well characterised. Human trial data is extensive and covered in the research section.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Patient communities consistently describe stronger appetite suppression than semaglutide and faster early weight loss, along with more nausea and injection-site reactions. A recurring phrase is that the constant background thinking about food simply switched off. The other side of these accounts is well represented too: weight returning after stopping, loss of muscle alongside fat, and grey-market vials with variable potency that users notice from week to week.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Nausea and vomiting
- Diarrhoea or constipation
- Injection-site reactions
- Gallbladder disease
- Pancreatitis (rare)
- Loss of lean mass during rapid weight reduction
Safety notes
Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Not for use in pregnancy. Slows gastric emptying, which matters before anaesthesia. Serious interactions with insulin and sulfonylureas. Self-dosing reconstituted powder introduces sterility, dosing-accuracy and cold-chain risks that the approved product avoids entirely.
Stacking
Not appropriate for informal stacking. Clinically combined with resistance training and high protein intake to protect lean mass.
Related compounds
Retatrutide
LY3437943 — triple GLP-1 / GIP / glucagon receptor agonist
Fat Loss & Metabolic
The triple agonist that produced the largest weight reductions yet reported in a randomised obesity trial.
Cagrilintide
Long-acting amylin analogue — studied in combination with semaglutide
Fat Loss & Metabolic
An amylin analogue built to sit alongside a GLP-1 and push appetite suppression further.
AOD-9604
hGH fragment 176–191
Fat Loss & Metabolic
A fragment of growth hormone sold for fat loss, with trial results far more modest than the marketing.